Bharat Immunologicals Selected Fundamentals

BIBCL -- India Stock  

INR 18.85  1.55  7.60%

The Macroaxis Fundamental Analysis lookup allows users to check a given indicator for any equity or select from a set of available indicators by clicking on the link to the right. Please note, not all equities are covered by this module due to inconsistencies in global equity categorizations. Please check also Equity Screeners to view more equity screening tools

Debt to Equity Analysis

Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Bharat Immunologicals 
D/E 
 = 
Total Debt 
Total Equity 
 = 
3.80 %

About Debt to Equity

High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging barrowing against the capital invested by the owners.
Compare to competition
According to company disclosure Bharat Immunologicals Biologicals Corp Ltd has Debt to Equity of 3.8%. This is much higher than that of the Healthcare sector, and significantly higher than that of Debt to Equity industry, The Debt to Equity for all stocks is over 1000% lower than the firm.

Bharat Immunologicals Fundamental Drivers Relationships

Bharat Immunologicals Biologicals Corp Ltd is rated below average in book value per share category among related companies. It is rated below average in ebitda category among related companies totaling about  4,330,243  of EBITDA per Book Value Per Share.

Peer Comparison

Bharat Immunologicals Gross Profit Comparison
Bharat Immunologicals is currently under evaluation in gross profit category among related companies.

Did you try this?

Run Equity Analysis Now
   

Equity Analysis

Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
All  Next Launch Equity Analysis

Thematic Opportunities

Explore Investment Opportunities
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked.
Explore Thematic Ideas
Explore Investing Ideas  

Fundamental Indicators

Current Bharat Immunologicals financial ratios